Last viewed:
aldx
Prices are updated after-hours
ALDX
|
$3.91
-0.51%
-0.51%
450K
|
Health Technology
(0.0% 1d)
(35.8% 1m)
(-56.9% 1y)
(0.0% 2d)
(-0.5% 3d)
(-1.8% 7d)
(21.56%
volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 230,282,453
http://www.aldeyra.com
Sec
Filling
|
Patents
| 20 employees
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
msa
add to watch list
Paper trade
email alert is off
Press-releases
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Published: 2024-04-18
(Crawled : 12:00)
- biospace.com/
ALDX
|
$3.91
-0.51%
-0.51%
450K
|
Health Technology
| 0.0%
| O: 1.53%
H: 2.52%
C: 0.25%
day
research
therapeutics
development
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-27
(Crawled : 13:00)
- biospace.com/
TVTX
|
$5.745
-1.8%
-1.83%
1.2M
|
Health Technology
| -26.31%
| O: 2.37%
H: 1.46%
C: 1.22%
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
| -1.52%
| O: -0.45%
H: 0.7%
C: 0.6%
HTGC
4
|
$18.85
0.86%
0.26%
900K
|
Finance
| 0.43%
| O: -2.77%
H: 0.47%
C: -0.27%
VKTX
|
$64.99
1.79%
1.75%
2M
|
Health Technology
| 68.74%
| O: 81.31%
H: 29.0%
C: 21.9%
VRNA
|
$15.6
-0.76%
-0.77%
360K
|
Health Technology
| -11.57%
| O: 2.1%
H: 2.83%
C: -0.5%
LGND
|
$69.97
2.1%
2.06%
140K
|
Health Technology
| -6.09%
| O: 14.46%
H: 11.02%
C: 4.72%
ALDX
|
$3.91
-0.51%
-0.51%
450K
|
Health Technology
| 6.83%
| O: 1.91%
H: 2.68%
C: 1.07%
year
financial
results
Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics
Published: 2024-01-10
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -9.46%
| O: 1.1%
H: 0.0%
C: 0.0%
NVO
|
News
|
$128.64
2.7%
-0.07%
3.7M
|
Health Technology
| 18.38%
| O: -0.33%
H: 0.35%
C: -1.5%
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
| 17.27%
| O: 0.67%
H: 0.85%
C: 0.21%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
| -9.47%
| O: 0.69%
H: 0.0%
C: 0.0%
ALDX
|
$3.91
-0.51%
-0.51%
450K
|
Health Technology
| 17.07%
| O: -1.8%
H: 0.46%
C: -2.44%
companies
therapeutics
growth
market
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
Published: 2024-01-04
(Crawled : 13:30)
- biospace.com/
ALDX
|
$3.91
-0.51%
-0.51%
450K
|
Health Technology
| 16.72%
| O: 0.9%
H: 1.18%
C: -1.18%
update
therapeutics
platform
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
Published: 2023-12-18
(Crawled : 23:00)
- biospace.com/
ALDX
|
$3.91
-0.51%
-0.51%
450K
|
Health Technology
| 29.47%
| O: 1.32%
H: 3.27%
C: -3.27%
adx-629
conference
dermatitis
trial
therapeutics
results
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Published: 2023-11-27
(Crawled : 23:00)
- biospace.com/
ALDX
|
$3.91
-0.51%
-0.51%
450K
|
Health Technology
| 54.55%
| O: -1.19%
H: 5.2%
C: 4.8%
reproxalap
drug
disease
food
treatment
eye
application
therapeutics
response
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap
Published: 2023-11-01
(Crawled : 12:00)
- biospace.com/
ABBV
|
News
|
$169.54
0.98%
-0.91%
4.1M
|
Health Technology
| 19.59%
| O: 0.06%
H: 1.3%
C: 0.43%
ALDX
|
$3.91
-0.51%
-0.51%
450K
|
Health Technology
| 128.65%
| O: 16.96%
H: 36.5%
C: 27.0%
reproxalap
abbvie
license
therapeutics
agreement
NSSC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds NAPCO Security Technologies, Inc. Investors with Losses to Actively Participate in the Class Action Lawsuit!
Published: 2023-10-25
(Crawled : 22:00)
- prnewswire.com
KVUE
4
|
$19.37
-1.07%
0.0%
20M
|
n/a
| -1.82%
| O: -4.46%
H: 1.49%
C: -0.85%
NSSC
|
$43.345
4.67%
4.46%
710K
|
Producer Manufacturing
| 119.9%
| O: -0.81%
H: 1.54%
C: 0.1%
ALDX
|
$3.91
-0.51%
-0.51%
450K
|
Health Technology
| 152.26%
| O: 0.65%
H: 1.92%
C: 0.64%
security
APLS NOTICE: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Published: 2023-09-24
(Crawled : 20:20)
- prnewswire.com
ALDX
|
$3.91
-0.51%
-0.51%
450K
|
Health Technology
| Email alert
Add to watchlist
APLS
G
|
$48.69
2.2%
2.16%
1.2M
|
Health Technology
| Email alert
Add to watchlist
DFS
|
$129.24
2.02%
0.0%
1.8M
|
Finance
| Email alert
Add to watchlist
trusted
deadline
ALDX FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX
Published: 2023-09-24
(Crawled : 16:20)
- prnewswire.com
ALDX
|
$3.91
-0.51%
-0.51%
450K
|
Health Technology
| Email alert
Add to watchlist
DFS
|
$129.24
2.02%
0.0%
1.8M
|
Finance
| Email alert
Add to watchlist
KVUE
4
|
$19.37
-1.07%
0.0%
20M
|
n/a
| Email alert
Add to watchlist
deadline
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0001062993-24-008171
4
2024-04-08
2024-04-05
Buy
P
37712
9275851
0001062993-24-008171
4
2024-04-08
2024-04-04
Buy
P
140281
9238139
0000950170-24-030314
4
2024-03-13
2024-03-09
Buy
A
252280
252280
0000950170-24-030314
4
2024-03-13
2024-03-11
Sell
S
13201
120699
0000950170-24-030311
4
2024-03-13
2024-03-09
Buy
A
405450
405450
0000950170-24-030311
4
2024-03-13
2024-03-12
Sell
S
11537
243495
0000950170-24-030311
4
2024-03-13
2024-03-11
Sell
S
18231
255032